Yesafili (aflibercept-jbvf) / Biocon - LARVOL DELTA

Beyond Cost: Faricimab as a Driver of Service Efficiency and Quality in Neovascular Age-Related Macular Degeneration Care. (PubMed, Ophthalmol Ther) - "In capacity-constrained settings, more durable options like faricimab can unlock operational capacity, enabling health systems to treat more patients, reduce delays, and more effectively achieve quality standards. These improvements not only help preserve vision but also generate economic value, as operational efficiencies can reduce service and litigation costs, complementing potential reductions in acquisition costs."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy and safety of aflibercept biosimilars compared to aflibercept in the treatment of neovascular age-related macular degeneration: a systematic review and meta-analysis. (PubMed, Front Pharmacol) - "This study aimed to evaluate the aflibercept biosimilars compared to the reference product aflibercept (Eylea®) in terms of efficacy, safety, and immunogenicity in patients with neovascular age-related macular degeneration (nAMD)...There were no statistically significant differences in visual and anatomical outcomes between the aflibercept biosimilars (SB15, P041, SDZ-AFL, AVT06, SCD411, ABP 938, and QL1207) and the reference aflibercept...Based on the seven included randomized controlled clinical trials, aflibercept biosimilars demonstrated comparable safety and efficacy to the reference aflibercept. Future research requires more rigorous studies."

Clinical • Journal • Retrospective data • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study. (PubMed, Eye (Lond)) - No abstract available

Journal

Short-term outcomes of aflibercept biosimilar SB15 in macular edema secondary to retinal vein occlusion. (PubMed, BMC Ophthalmol) - No abstract available

Journal • Macular Edema • Ophthalmology • Retinal Vein Occlusion

A Phase III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea® in Patients with Wet Age-Related Macular Degeneration. (PubMed, Ophthalmol Ther) - "Efficacy, immunogenicity, and safety profiles of ZRC-3285 were found to be similar to those of Eylea®."

Journal • P3 data • Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Therapeutic Equivalence of Eyluxvi (Aflibercept) to Eylea in Neovascular Age-Related Macular Degeneration: ALTERA Trial (Randomized). (PubMed, Ophthalmol Ther) - P3 | "This study demonstrated therapeutic equivalence between Eyluxvi and Eylea in nAMD treatment, with comparable anatomical outcomes and safety profiles. These findings support the development of Eyluxvi as an aflibercept biosimilar, potentially increasing treatment accessibility for patients with nAMD."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration. (PubMed, BMJ Open Ophthalmol) - P3 | "Although conducted during the COVID-19 pandemic in a potentially vulnerable elderly population and affected by geopolitical disruption in Ukraine, mitigation measures minimised the overall impact of these events. FYB203 demonstrated therapeutic equivalence to reference aflibercept in patients with nAMD, supporting similar clinical performance across all approved indications."

Clinical • Journal • Age-related Macular Degeneration • Diabetic Retinopathy • Infectious Disease • Macular Degeneration • Novel Coronavirus Disease • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Biocon Biologics signs settlement and license agreement to commercialize biosimilar Aflibercept (Indian Pharma Post) - "These agreements grant Biocon Biologics the necessary clearance to globally commercialize Yesafili, its biosimilar Aflibercept (40mg/ml)....By executing this agreement, all pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed. The resolution enables the launch of Yesafili in the United Kingdom in January 2026 and in the remaining settled countries starting in March 2026, or potentially sooner under certain conditions. The specific financial and legal terms of the settlement remain confidential."

Biosimilar launch • Licensing / partnership • Ophthalmology

Efficacy and safety of aflibercept biosimilars compared to reference aflibercept for retinal diseases: A systematic review and meta-analysis. (PubMed, Surv Ophthalmol) - "Biosimilar aflibercept show similar efficacy and safety to the original for nAMD and DME, with no significant differences in key outcomes. They offer a cost-effective alternative that offers similar clinical benefits while improving treatment accessibility."

Journal • Retrospective data • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

The Cost of Pressure: Quantifying the Consequences of Clinical Strain in Ophthalmology (ISPOR-EU 2025) - "Innovative therapies that are more durable in clinical practice have the potential to significantly improve key clinical service indicators, reduce service pressures and mitigate litigation-related costs."

Clinical • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Comparative efficacy of intravitreal aflibercept biosimilar QL1207 versus reference aflibercept in the treatment of diabetic macular edema. (PubMed, Front Med (Lausanne)) - "Furthermore, no cardiovascular or cerebrovascular events were reported during the treatment period. Both the reference aflibercept and its biosimilar QL1207 demonstrate comparable efficacy in the treatment of DME, effectively reducing macular edema, improving BCVA, and enhancing macular perfusion status."

Journal • Cardiovascular • Cataract • Diabetic Macular Edema • Glaucoma • Hematological Disorders • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Comparative outcomes of aflibercept biosimilars and reference aflibercept in nAMD: a systematic review and meta-analysis. (PubMed, BMJ Open Ophthalmol) - "This systematic review and meta-analysis found no statistically significant differences in functional, anatomical or safety outcomes between aflibercept biosimilars and the reference product for nAMD, based on moderate to high certainty evidence. Functional and anatomical outcomes appeared stable across multiple timepoints. Further long-term pharmacovigilance studies and real-world data beyond 56 weeks are warranted."

Clinical • Journal • Retrospective data • Review • Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Development of Biosimilar Aflibercept SDZ-AFL. (PubMed, Curr Ther Res Clin Exp) - "In 2024, Sandoz biosimilar aflibercept (SDZ-AFL; SOK583A1, Enzeevu/Afqlir) was approved by the US Food and Drug Administration and the European Medicines Agency as a biosimilar of reference aflibercept (Ref-AFL; Eylea, a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc) based on a comprehensive package of data. This comprehensive totality of evidence has established biosimilarity between SDZ-AFL and Ref-AFL based on comparable physicochemical and biological characteristics, as well as similarity in clinical efficacy, safety, and immunogenicity. The introduction of aflibercept biosimilars to the market is anticipated to reduce barriers to access, potentially increasing the number of appropriate patients with retinal diseases benefiting from this biologic therapy."

Journal • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Biocon Gets CDSCO Panel Nod to Import Aflibercept Injection for Eye Disorders, Phase IV Trial Mandated (Medical Dialogues) - "The company presented its proposal for grant of marketing authorization for Aflibercept solution for injection (40 mg/ml) based on the results of a global clinical trial in which India was a participating country, specifically for Diabetic Macular Oedema (DME)....The regulator further directed that, 'Accordingly, firm shall submit Phase IV Clinical Trial protocol to CDSCO within 03 months of grant of marketing authorization permission'."

Approval • Clinical protocol • Diabetic Macular Edema • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Biocon Biologics' Yesafili (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases (Canada Newswire) - "YESAFILI (aflibercept) is approved for treating neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular edema secondary to central or branch retinal vein occlusion (CRVO/BRVO), diabetic macular edema (DME) and myopic choroidal neovascularization (myopic CNV)."

Reimbursement • Diabetic Macular Edema • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

SDZ-AFL: An Aflibercept Biosimilar. (PubMed, Clin Drug Investig) - "SDZ-AFL (SOK583A1; Afqlir®) is a biosimilar of the reference intravitreal aflibercept, a vascular endothelial growth factor inhibitor...The tolerability, safety and immunogenicity profiles of SDZ-AFL were similar to those of reference aflibercept. The role of reference aflibercept in the management of neovascular retinal diseases is well established, and SDZ-AFL provides an effective biosimilar alternative for patients requiring ophthalmic aflibercept therapy."

Journal • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Clinical Trials of Aflibercept Biosimilars: A Review. (PubMed, J Ocul Pharmacol Ther) - "Following the patent expiration of ranibizumab, multiple anti-VEGF biosimilars have been developed, with the first approved for ophthalmic use entering the market in 2022. Understanding the study designs of biosimilars can mitigate negative perceptions of biosimilars and promote their active implementation. In this review, we provide a comprehensive comparison of the designs of phase III clinical trials of aflibercept biosimilars, including recently published results."

Journal • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. (PubMed, Clin Ophthalmol) - "Aflibercept biosimilars demonstrated comparable efficacy and safety profiles to reference aflibercept in the treatment of nAMD. These findings suggest that biosimilars may serve as a cost-effective alternative without compromising patient outcomes."

Journal • Retrospective data • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Biocon Biologics gets Health Canada approval for its AMD biosimilar Yesafili (New Indian Express) - "Biocon Biologics, the biosimilars subsidiary of Biocon Ltd, said on Friday that Health Canada has granted a Notice of Compliance (NOC) for its age-related macular degeneration (AMD) drug, Yesafili. The drug is a biosimilar to aflibercept, marketed under the brand name Eylea by US biotech major Regeneron Pharmaceuticals. This approval clears the way for the Canadian launch of Yesafili injection on July 4, 2025, making it the first biosimilar to Eylea approved by Health Canada."

Biosimilar launch • Canada approval • Wet Age-related Macular Degeneration

Systematic review of efficacy and meta-analysis of safety of aflibercept biosimilars relative to reference aflibercept anti-VEGF therapy for neovascular AMD treatment (SOE 2025) - "Conversely, we excluded studies that did not provide visual outcome data following intravitreal injections of biosimilar and reference ranibizumab, those that combined anti-VEGF treatments with laser or steroid injections, studies using sham injections as a control, non-English full texts, and those with non-comparative, observational designs. Our cohort included a total of 2,039 patients diagnosed with neovascular age-related macular degeneration, who received either reference Aflibercept (n = 1,016, 49.8%) or Aflibercept biosimilars (n = 1,023; 50.2%). This systematic review of four RCTs demonstrated no significant difference in visual outcomes, retinal thickness outcomes, as well as meta-analysis of adverse events between biosimilar and reference Aflibercept therapies for nAMD treatment."

Retrospective data • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Biocon Biologics Secures Market Entry Date for Yesafili, an Interchangeable Biosimilar to Eylea, in the U.S. (PRNewswire) - "Biocon Biologics Ltd (BBL)...announced today a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept, in the United States....Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending appeal at the United States Court of Appeals for the Federal Circuit (USCAFC) of patent US11084865 ('865 patent) and the pending litigation at the U.S. District Court for the Northern District of West Virginia, Clarksburg Division. This agreement enables the Company to launch in the United States in the second half of calendar year 2026 or earlier in certain circumstances....YESAFILI is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME)..."

Biosimilar launch • Licensing / partnership • Patent • Age-related Macular Degeneration • Diabetic Macular Edema • Retinal Vein Occlusion

Randomized Trial of MYL-1701P (Proposed Aflibercept Biosimilar) vs. Aflibercept Through 76 Weeks in DME, Including Switch From Aflibercept (AAO 2024) - "Adjusted mean difference in change in best corrected visual acuity between baseline and Week 76 (switch minus continuation arm) was −1.20 ETDRS letters (90% CI, −6.15 to 3.75). Conclusion Similar safety, efficacy and immunogenicity profiles were observed between those who continued to receive MYL-1701P and those who switched to it from aflibercept."

Clinical • Ophthalmology

Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial. (PubMed, JAMA Ophthalmol) - P3 | "To compare efficacy and safety of MYL-1701P, an aflibercept biosimilar, with reference aflibercept (Eylea [Regeneron]) in DME. These findings support use of MLY-1701P as an alternative to reference aflibercept. ClinicalTrials.gov Identifier: NCT03610646."

Clinical • Journal • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders • Type 2 Diabetes Mellitus

Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili. Enters U.S. Ophthalmology Market (PRNewswire) - "Biocon Biologics Ltd (BBL)...announced that the U.S. Food and Drug Administration (US FDA) has approved the Company's first-to-file application for Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product EYLEA (aflibercept)....The Company has secured a launch date in Canada of no later than July 1, 2025, under the terms of a settlement agreement."

Biosimilar launch • FDA approval • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Wet Age-related Macular Degeneration

Biocon Biologics Secures Canada Market Entry Date for YESAFILI, a Proposed Biosimilar to EYLEA (Biocon Press Release) - "Biocon Biologics Ltd (BBL)...has announced the signing of a settlement with Bayer Inc. and Regeneron Pharmaceuticals, Inc. This Agreement paves the way for the introduction of YESAFILI, a proposed biosimilar to EYLEA (aflibercept) Injection, into the Canadian market. Under the terms of the agreement, Biocon Biologics has secured a launch date for YESAFILI 2 mg NDS for vials and prefilled syringes (yet to be filed), set no later than July 1, 2025."

Launch Canada • Licensing / partnership • Age-related Macular Degeneration • Diabetic Macular Edema • Ophthalmology • Wet Age-related Macular Degeneration